Project Details
Description
An open-label, multi-center phase 1/2 study of Surufatinib in combination with gemcitabine in pediatric patients with recurrent or refractory solid tumors
| Status | Active |
|---|---|
| Effective start/end date | 6/28/21 → 6/27/24 |
Funding
- PUBLIC HEALTH INSTITUTE
- HUTCHMED INTERNATIONAL CORPORATION
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.